Follow-up of differentiated thyroid cancer: What is the value of FDG and sestamibi in the diagnostic algorithm?

NuklearMedizin

Volumn 37, Issue 1, 1998, Pages 6-11

  Dietlein, M ^a   Scheidhauer, K ^a   Voth, E ^a   Theissen, P ^a   Schicha, H ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

FDG PET; Radioiodine; Scintigraphy; Sestamibi; Thyroid Cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID CANCER; WHOLE BODY SCINTISCANNING;

EID: 0031818594     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1629699     Document Type: Article

References (19)

1. Biedermann M, Bares R, Grün B, Dohmen BM, Sabri O, Friedberg C. Bull U The follow-up of differentiated thyroid cancer: Clinical experience with magnetic resonance imaging and oncoscintigraphy using technetium-99m labelled MIBI. Nuklearmedizin 1995; 34: 87-91.
2. Briele B, Hotze A, Kropp J, Bockisch A, Overbeck B, Grünwald F. Kaiser W, Biersack HJ. Comparison of 201 T1 and 99m TcMIBI in the follow-up of differentiated thyroid carcinomas. Nuklearmedizin 1991; 30: 115-24.
3. Burman KD, Anderson JH, Wartofsky L, Mong DP, Jelinek JJ. Management of patients with thyroid carcinoma: Application of thallium-201 scintigraphy and magnetic resonance imaging. J Nucl Med 1990; 31: 1958-64.
4. Dadparvar S, Chevres A, Tulchinsky M, Krishna-Badrinath L, Khan AS, Slizofski WJ. Clinical utility of technetium-99m methoxyisobutylisonitrile imaging in differentiated thyroid carcinoma: Comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulm quantitation. Eur J Nucl Med 1995; 22: 1330-8.
5. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. FDG-PET in der Nachsorge differenzierter Schilddrüsenkarzinome. Wann ist ein Einfluß auf das diagnostische und therapeutische Outcome zu erwarten? Nuklearmedizin 1997; 36: A68.
6. Elser H, Henze M, Hermann C, Eckert W, Mende U. Follow-up of differentiated thyroid carcinoma by 99m Tc-MIBI. Nuklearmedizin 1997; 36: 7-12.
7. Feine U, Lietzenmayer R, Hanke J-P, Held J, Wohrle H, Muller-Schauenburg W. Fluorine-1 S-FDG and Iodine-131-Iodide uptake in thyroid cancer. J Nucl Med 1996; 37: 1468-72.
8. Feine U, Lietzenmayer R, Hanke J-P, Wöhrle H, Müller-Schauenburg W. Whole body 18F-fluorodeoxyglucose positron emission tomography (WB FDG PET) in differentiated thyroid cancer - Flipflop-behaviour in uptake patterns of 18 FDG and 131 I. Nuklearmedizin 1995; 34: 127-34.
9. 131I in patients with metastatic thyroid carcinoma. Nucl Med Comm 1997; 18: 3-9.
10. Grünwald F, Schomburg A, Bender H, Klemm E, Menzel C, Bultmann T, Palmedo H, Ruhlmann J, Kozak B, Biersack H-J. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1996; 23: 312-9.
11. Iida Y, Hidaka A, Hatabu H, Kasagi K, Konishi J. Follow-up study of postoperative patients with thyroid cancer by Thallium-201 scintigraphy and scrum thyroglobulin measurement. J Nucl Med 1990; 32: 2098-100.
12. Joensuu H, Ahonen A, Imaging of metastases of thyroid carcinoma with fluorine-18-fluorodeoxyglucose. J Nucl Med 1987; 28: 910-4.
13. Nemec J, Nyvltova O, Blazek T, Vlecek P, Racek P, Novak Z, Preiningerova M, Hubackova M, Krizova M, Zimak J, Bilek R. Positive thyroid cancer scintigraphy using technetium-99m methoxyisobutylisonitrile. Eur J Nucl Med 1996; 23: 69-71.
14. Scheidhauer K, Dietlein M, Voth E, Theissen P, Schicha H. Kann 99m Tc-MIBI-SPECT 18F-FDG-PET im follow-up differenzierter Schilddrüsenkarzinome ersetzen? Nuklearmedizin 1997; 36: A68.
15. Schicha H, Scheidhauer K. Therapie mit offenen radioaktiven Stoffen. In: Nuklearmedizin. Büll U, Schicha H. (eds). Stuttgart: Thieme 1996; 460-87.
16. Scott GC, Meier DA, Dickinson CZ. Cervical lymph node metastasis of thyroid papillary carcinoma imaged with fluorine-18-FDG, technetium-99m-pertechnetate and iodine-131-sodium iodide. J Nucl Med 1995; 36: 1843-5.
17. Sisson JC, Ackermann RJ, Meyer MA, Wahl RL. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: Implications for diagnosis and therapy. J Clin Endocrinol Metab 1993; 77: 1090-4.
18. Sundram FX, Goh AS, Ang ES. Role of technetium-99m sestamibi in localisation of thyroid cancer metastases. Ann Acad Med Singapore 1993; 22: 557-9.
19. 131I imaging in the follow-up of patients with well-differentiated thyroid carcinoma. Nucl Med Comm 1996; 17: 373-7.